Familial gastric cancer: Detection of a hereditary cause helps to understand its etiology

Hereditary Cancer in Clinical Practice

Volumn 10, Issue 1, 2012, Pages

  Vogelaar, Ingrid P ^a   van der Post, Rachel S ^a   Bisseling, Tanya M ^a   van Krieken, J Han J M ^a   Ligtenberg, Marjolijn J L ^a   Hoogerbrugge, Nicoline ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CDH1; E cadherin; Gastric cancer; Genetics; Hereditary diffuse gastric cancer

Indexed keywords

BETA CATENIN; PLAKOGLOBIN; UVOMORULIN;

ABDOMINAL PAIN; ADENOMATOUS POLYP; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; COWDEN SYNDROME; DIET; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; HELICOBACTER INFECTION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITY; HERITABILITY; HETEROZYGOTE DETECTION; HIGH RISK BEHAVIOR; HISTOPATHOLOGY; HUMAN; LACTOSE INTOLERANCE; MALABSORPTION; PEUTZ JEGHERS SYNDROME; POSTGASTRECTOMY SYNDROME; REVIEW; SALT INTAKE; SMOKING; STEATORRHEA; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; TOTAL STOMACH RESECTION;

HELICOBACTER PYLORI;

EID: 84870893188     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-10-18     Document Type: Review

References (63)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer incidence in Five Continents 2007, Lyon, France: IARC Scientific publication.
3. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 2008, 47:1077-1083. 10.2169/internalmedicine.47.0975, 18552463.
4. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System 2010, Lyon, France: IARC, 4.
5. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
6. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002, 97:72-81. 10.1002/ijc.1571, 11774246.
7. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El-Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009, 10:321-322. 10.1016/S1470-2045(09)70096-8, 19350698.
8. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992, 52:6735-6740.
9. Helicobacter and Cancer Collaborative Group Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001, 49:347-353. 10.1136/gut.49.3.347, 1728434, 11511555, Helicobacter and Cancer Collaborative Group.
10. no authors listed Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994, 61:177-240. no authors listed.
11. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002, 347:1175-1186. 10.1056/NEJMra020542, 12374879.
12. Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, Lunet N. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008, 19:689-701. 10.1007/s10552-008-9132-y, 18293090.
13. Gonzalez CA, Lopez-Carrillo L. Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis. Scand J Gastroenterol 2010, 45:6-14. 10.3109/00365520903401959, 20030576.
14. La Vecchia C, Negri E, Franceschi S, Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer 1992, 70:50-55. 10.1002/1097-0142(19920701)70:1<50::AID-CNCR2820700109>3.0.CO;2-I, 1606546.
15. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994, 86:1600-1608. 10.1093/jnci/86.21.1600, 7932824.
16. Stone J, Bevan S, Cunningham D, Hill A, Rahman N, Peto J, Marossy A, Houlston RS. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer 1999, 79:1935-1937. 10.1038/sj.bjc.6690308, 2362779, 10206317.
17. Kaurah P, MacMillan A, Boyd N, Senz J, De LA, Chun N, Suriano G, Zaor S, Van ML, Gilpin C, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007, 297:2360-2372. 10.1001/jama.297.21.2360, 17545690.
18. Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten J, Fitzgerald R, Vogelsang H, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009, 18:1545-1555. 10.1093/hmg/ddp046, 2667284, 19168852.
19. Corso G, Pedrazzani C, Pinheiro H, Fernandes E, Marrelli D, Rinnovati A, Pascale V, Seruca R, Oliveira C, Roviello F. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer 2011, 47:631-639. 10.1016/j.ejca.2010.10.011, 21106365.
20. Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res 2000, 6:2994-2998.
21. Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, Vasen HF, Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010, 138:487-492. 10.1053/j.gastro.2009.10.051, 19900449.
22. Sereno M, Aguayo C, Guillen PC, Gomez-Raposo C, Zambrana F, Gomez-Lopez M, Casado E. Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention. Clin Transl Oncol 2011, 13:599-610. 10.1007/s12094-011-0705-y, 21865131.
23. van Lier MG, Westerman AM, Wagner A, Looman CW, Wilson JH, de Rooij FW, Lemmens VE, Kuipers EJ, Mathus-Vliegen EM, van Leerdam ME. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2011, 60:141-147. 10.1136/gut.2010.223750, 21205875.
24. Oliveira C, Ferreira P, Nabais S, Campos L, Ferreira A, Cirnes L, Alves CC, Veiga I, Fragoso M, Regateiro F, et al. E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer 2004, 40:1897-1903. 10.1016/j.ejca.2004.04.027, 15288293.
25. Keller G, Vogelsang H, Becker I, Plaschke S, Ott K, Suriano G, Mateus AR, Seruca R, Biedermann K, Huntsman D, et al. Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 2004, 41:e89. 10.1136/jmg.2003.015594, 1735803, 15173255.
26. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, Riegert-Johnson D, Foretova L, Silva EM, Digianni L, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011, 13:651-657. 10.1097/GIM.0b013e31821628b6, 21552135.
27. Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 2002, 87:888-891. 10.1038/sj.bjc.6600562, 2376177, 12373604.
28. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005, 7:60. 1681718, 16614682.
29. Iwama T, Mishima Y, Utsunomiya J. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 1993, 217:101-108. 10.1097/00000658-199302000-00002, 1242747, 8382467.
30. Park SY, Ryu JK, Park JH, Yoon H, Kim JY, Yoon YB, Park JG, Lee SH, Kang SB, Park JW, Oh JH. Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in korean patients with familial adenomatous polyposis. Gut Liver 2011, 5:46-51. 10.5009/gnl.2011.5.1.46, 3065092, 21461071.
31. Lynch HT, Snyder C, Davies JM, Lanspa S, Lynch J, Gatalica Z, Graeve V, Foster J. FAP, gastric cancer, and genetic counseling featuring children and young adults: a family study and review. Fam Cancer 2010, 9:581-588. 10.1007/s10689-010-9352-7, 20532639.
32. Win AK, Hopper JL, Jenkins MA. Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 2011, 10:1-9.
33. Pollock J, Welsh JS. Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol 2011, 34:332-336. 10.1097/COC.0b013e3181dea432, 20859198.
34. Stanich PP, Francis DL, Sweetser S. The spectrum of findings in Cowden syndrome. Clin Gastroenterol Hepatol 2011, 9:e2-e3. 10.1016/j.cgh.2010.07.003, 3246637, 21699807.
35. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 2000, 157:747-754. 10.1016/S0002-9440(10)64588-9, 1885693, 10980114.
36. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009, 10:400-408. 10.1016/S1470-2045(09)70041-5, 19341971.
37. Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. J Surg Oncol 2005, 90:114-133. 10.1002/jso.20214, 15895459.
38. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405. 10.1038/32918, 9537325.
39. Berx G, Becker KF, Hofler H, van RF. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998, 12:226-237. 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D, 9744472.
40. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, van Krieken JH, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436-444. 10.1136/jmg.2009.074237, 2991043, 20591882.
41. Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol 2008, 61:25-30.
42. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001, 121:1348-1353. 10.1053/gast.2001.29611, 11729114.
43. Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, Harawira P, McLeod M, Parry S, Charlton A, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006, 4:262-275. 10.1016/j.cgh.2005.12.003, 16527687.
44. Humar B, Guilford P. Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer Sci 2009, 100:1151-1157. 10.1111/j.1349-7006.2009.01163.x, 19432899.
45. Nejsum LN, Nelson WJ. A molecular mechanism directly linking E-cadherin adhesion to initiation of epithelial cell surface polarity. J Cell Biol 2007, 178:323-335. 10.1083/jcb.200705094, 2064450, 17635938.
46. Drubin DG, Nelson WJ. Origins of cell polarity. Cell 1996, 84:335-344. 10.1016/S0092-8674(00)81278-7, 8608587.
47. Lechler T, Fuchs E. Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature 2005, 437:275-280. 10.1038/nature03922, 1399371, 16094321.
48. Lu B, Roegiers F, Jan LY, Jan YN. Adherens junctions inhibit asymmetric division in the Drosophila epithelium. Nature 2001, 409:522-525. 10.1038/35054077, 11206549.
49. Norton JA, Ham CM, Van DJ, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007, 245:873-879. 10.1097/01.sla.0000254370.29893.e4, 1876967, 17522512.
50. Fitzgerald RC, Caldas C. E-cadherin mutations and hereditary gastric cancer: prevention by resection?. Dig Dis 2002, 20:23-31. 10.1159/000063162, 12145417.
51. Miholic J, Meyer HJ, Muller MJ, Weimann A, Pichlmayr R. Nutritional consequences of total gastrectomy: the relationship between mode of reconstruction, postprandial symptoms, and body composition. Surgery 1990, 108:488-494.
52. Cisco RM, Ford JM, Norton JA. Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer 2008, 113:1850-1856. 10.1002/cncr.23650, 18798546.
53. Barber ME, Save V, Carneiro F, Dwerryhouse S, Lao-Sirieix P, Hardwick RH, Caldas C, Fitzgerald RC. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 2008, 216:286-294. 10.1002/path.2415, 18825658.
54. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004, 53:814-820. 10.1136/gut.2002.010447, 1774074, 15138207.
55. Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 1992, 79:241-244. 10.1002/bjs.1800790319, 1313325.
56. Lee AF, Rees H, Owen DA, Huntsman DG. Periodic acid-schiff is superior to hematoxylin and eosin for screening prophylactic gastrectomies from CDH1 mutation carriers. Am J Surg Pathol 2010, 34:1007-1013. 10.1097/PAS.0b013e3181e28985, 20534996.
57. Park CM, Reid PE, Walker DC, MacPherson BR. A simple, practical 'swiss roll' method of preparing tissues for paraffin or methacrylate embedding. J Microsc 1987, 145:115-120. 10.1111/j.1365-2818.1987.tb01321.x, 2437310.
58. Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?. Cancer 2001, 92:181-187. 10.1002/1097-0142(20010701)92:1<181::AID-CNCR1307>3.0.CO;2-J, 11443625.
59. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001, 344:1904-1909. 10.1056/NEJM200106213442504, 11419427.
60. Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, Caldas C, Sobrinho-Simoes M. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004, 203:681-687. 10.1002/path.1564, 15141383.
61. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 2006, 14:21-33. 10.1177/106689690601400105, 16501831.
62. Kluijt I, Sijmons RH, Hoogerbrugge N, Plukker JT, De JD, van Krieken JH, Van HR, Ligtenberg M, Bleiker E, Cats A. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer 2012, 11:363-369. 10.1007/s10689-012-9521-y, 22388873.
63. Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut 2004, 53:775-778. 10.1136/gut.2003.022061, 1774077, 15138199.